Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

SGLT2 Inhibitors and the Diabetic Kidney.

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

nents, can lead to de novo ESRD in subjects without identifiable ESRD risks. These data also increase the urgency to identify kidney toxic dietary components and if these components can promote ESRD even in subjects who have no identifiable risk factors. Diet remains a relatively underused component of the clinician’s armamentarium in the fight to prevent patients with CKD progressing to ESRD a...

Covid-19 infection in kidney transplant recipients: a case report

Anti-inflammatory effects of pioglitazone in diabetic kidney transplant recipients.

Cataract in kidney transplant recipients.

The relationship between the administrated dose of steroid and the grade of cataract was studied in 22 kidney transplant recipients maintaining a good graft function for more than one year. Posterior subcapsular cataract was observed in 19 patients, of whom seven showed severe cataract accompanied by visual disturbance. The total dose of steroid, particularly the dose in the period from three m...